Modern Diagnostic & Research Centre IPO Details
Modern Diagnostic & Research Centre IPO Summary
Modern Diagnostic & Research Centre IPO opens for subscription on 31 Dec 2025 and closes on 02 Jan 2026.The IPO will be listed on BSE with the tentative listing date set for 07 Jan 2026.
Modern Diagnostic & Research Centre IPO price band has been fixed at ₹85 – ₹90 per share. The face value is ₹10 per share with a lot size of 1600.
Modern Diagnostic & Research Centre IPO total issue size comprises 40,99,200 shares (aggregating up to ₹36.89 Cr.). This includes a fresh issue of 40,99,200 shares (aggregating up to ₹36.89 Cr.). Pre-issue shareholding stands at 1,10,00,000, which will increase to 1,50,99,200 post-issue.
Modern Diagnostic & Research Centre IPO carries a ₹14 (15.56%) GMP, reflecting investor sentiment.
Modern Diagnostic & Research Centre IPO Lot Size :Individual Minimum is 2 lots (3,200 shares) amounting to ₹288,000. Individual Maximum is 2 lots (3,200 shares) amounting to ₹288,000. SHNI Minimum is 3 lots (4,800 shares) amounting to ₹432,000. SHNI Maximum is 6 lots (9,600 shares) amounting to ₹864,000. BHNI Minimum is 7 lots (11,200 shares) amounting to ₹1,008,000.
The Lead Managers for Modern Diagnostic & Research Centre IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Beeline Capital Advisors Pvt Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For SME (Small and Medium-sized Enterprise) IPOs, a Market Maker is appointed to ensure liquidity and stability for the stock once it is listed. They do this by continuously quoting bid and ask prices, ensuring there is a market for the shares. The appointed market maker for this IPO is Spread X Securities. You can analyze their track record by checking the Market Maker Performance Summary report.
For detailed information, Refer to the Modern Diagnostic & Research Centre Limited RHP.
Modern Diagnostic & Research Centre IPO Details
Modern Diagnostic & Research Centre IPO Subscription
Modern Diagnostic & Research Centre IPO Application Wise Breakup
Modern Diagnostic & Research Centre IPO Dates
- 31 Dec 2025Opening dateOpen
- 02 Jan 2026Closing dateClose
- 05 Jan 2026Allotment Date Allotment
- 06 Jan 2026Initiation of RefundsRefund
- 06 Jan 2026Credit of SharesCredit
- 07 Jan 2026Listing dateListing
Modern Diagnostic & Research Centre IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual Minimum | 2 | 3200 | ₹288,000 |
| Individual Maximum | 2 | 3200 | ₹288,000 |
| SHNI Minimum | 3 | 4800 | ₹432,000 |
| SHNI Maximum | 6 | 9600 | ₹864,000 |
| BHNI Minimum | 7 | 11200 | ₹1,008,000 |
Modern Diagnostic & Research Centre IPO Reservation
Promoter Holding
Documents
Modern Diagnostic & Research Centre IPO Valuations
Modern Diagnostic & Research Centre Financial Information
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 77.86 | 64.57 | 49.49 | 36.54 |
| Total Income | 22.67 | 78.80 | 68.67 | 56.61 |
| Profit After Tax | 3.00 | 8.97 | 5.79 | -5.73 |
| EBITDA | 5.86 | 17.96 | 11.05 | -0.99 |
| NET Worth | 23.72 | 20.73 | 11.76 | 5.96 |
| Reserves and Surplus | 12.72 | 9.73 | 10.76 | 4.96 |
| Total Borrowing | 30.38 | 22.09 | 20.46 | 15.31 |
| Amount in ₹ Crore | ||||
About Modern Diagnostic & Research Centre IPO
Incorporated in 1985, Modern Diagnostic & Research Centre Limited (MDRC) is a well-established diagnostic service provider in India, offering a comprehensive portfolio of pathology and radiology solutions. The Company focuses on delivering accurate, reliable, and timely diagnostic services to patients, hospitals, corporates, and institutional clients.
MDRC provides an extensive range of diagnostic offerings, including pathology testing, advanced radiology imaging, preventive health check-ups, and customized test packages. The Company also offers home specimen collection and digital report delivery, enhancing accessibility and convenience for patients.
As of the latest period, MDRC operates a network of 21 diagnostic facilities, comprising 18 laboratories and 3 diagnostic centers, spread across 8 states in India. Its radiology services include ultrasound, CT scan, MRI, X-ray, ECG, pulmonary function tests (PFT), and specialized diagnostic services for cardiac and neurological care.
Key Service Segments
- Pathology Services:
Provides a wide range of routine and specialized tests, including molecular diagnostics, cytogenetics, and advanced panels for genetic disorders and oncology. - Radiology Services:
Offers advanced imaging solutions such as MRI, CT scans, ultrasound, and digital X-rays, supported by modern infrastructure including a 3-Tesla MRI machine and a 128-slice CT scanner. - Home Sample Collection:
Enables at-home blood and sample collection services across select cities, catering to patients requiring added convenience.
With a strong legacy spanning nearly four decades, MDRC continues to focus on expanding its diagnostic capabilities, strengthening service quality, and leveraging technology to enhance patient experience across its growing network.
Strength Of Modern Diagnostic & Research Centre IPO
- Experienced Promoter and Management Team.
- Comprehensive diagnostics provider delivering all-in-one solution at cost-effective prices.
- Focus on quality and customer service.
- Centralized information technology platform.
Risk Of Modern Diagnostic & Research Centre IPO
- Any interruptions at our laboratories and diagnostic centres may affect our ability to process diagnostic tests, which in turn may adversely affect our business, results of operations and financial condition.
- Our business and prospects may be adversely affected if we are unable to maintain and grow our brand name and brand image.
- Majority of our operations are concentrated in state of Haryana and any adverse developments affecting Haryana could have an adverse effect on our business, results of operations and financial condition.
- We have certain outstanding litigation against us, an adverse outcome of which may adversely affect our business, reputation and results of operations.
- There may be significant dependence on key diagnostic equipment and core technology infrastructure, the failure of which could result in serious service disruptions.
- Our heavy reliance on pathology services as the primary revenue driver presents significant risks that could negatively impact our operations, financial performance, and long-term growth prospects.
- Failure to attract and retain skilled healthcare professionals and experienced technical staff may lead to compromised diagnostic service quality and negatively impact patient care delivery.
- We have experienced negative cash flows in the past. Any such negative cash flows in the future could affect our business, results of operations and prospects.
- Our Restated Financial Statements are prepared and signed by the Peer Review Auditor who is not Statutory Auditor of our Company as required under the provisions of ICDR.
- Our Company has incurred losses in last two financial years as per Restated Financial Statements, which may impact our financial performance.
Objectives Modern Diagnostic & Research Centre IPO
1. Funding capital expenditure for purchase of medical Equipments for diagnostic centre and laboratories
2. Funding Working Capital Requirement
3. Repayment of certain outstanding borrowings availed by the Company
4. General Corporate Expenses
Company Contact Details
Modern Diagnostic & Research Centre Limited
Plot No H-64,1st Floor BLK-H,
Bali Nagar City landmark near Khetar Pal Hospital,
Ramesh Nagar, West Delhi, New Delhi
Phone: 9999474297
Email: compliance@mdrcindia.com
Website: http://www.mdrcindia.com/
Registrar Contact Details
Modern Diagnostic & Research Centre FAQs
The Modern Diagnostic & Research Centre IPO is a SME public issue comprising 4099200 equity shares with a face value of ₹10 each, aggregating to a total issue size of ₹36.89 Cr.. The issue price has been fixed at ₹90 per equity share, and the minimum application size is 1600 shares.
The IPO opens for subscription on 31 Dec 2025, and closes on 02 Jan 2026.
MUFG Intime India Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the BSE
As of now, the current GMP stands at ₹14 (15.56%).
Quick Links
Comments
